Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Kamada, Baxalta deal

    Kamada Ltd. (Tel Aviv:KMDA;NASDAQ:KMDA), Ness Ziona, Israel Baxalta Inc. (NYSE:BXLT), Deerfield, Ill. Business: Transplant Baxalta partnered with Kamada to develop and fund an Israeli Phase I/II trial of Kamadas Glassia…

    Published on 8/3/2015
  • Microchip, Teva deal

    Microchip Biotechnologies Inc., Pleasanton, Calif. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Drug delivery The companies partnered to apply Microchips implantable drug delivery …

    Published on 8/3/2015
  • Mylan, Teva deal

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Generics Teva withdrew its April proposal to acquire all outstanding ordinary share of Mylan for $…

    Published on 8/3/2015
  • Naurex, Allergan deal

    Naurex Inc., Evanston, Ill. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Neurology Allergan will acquire Naurex for $560 million up front, plus undisclosed R&D success-based and sales-threshold milestone payments.…

    Published on 8/3/2015
  • Novartis, Mereo BioPharma deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Mereo BioPharma Group Ltd., London, U.K. Business: Musculoskeletal, Pulmonary, Endocrine/Metabolic Start-up Mereo acquired three Phase II compounds from Novartis in …

    Published on 8/3/2015
  • Nuclea, Aelan Cell Technologies deal

    Nuclea Biotechnologies Inc., Pittsfield, Mass. Aelan Cell Technologies Inc., San Francisco, Calif. Business: Pharmacogenetics Nuclea and Aelan partnered to develop biomarker tests and companion diagnostics using human …

    Published on 8/3/2015
  • Paradigm, Cure Forward deal

    Paradigm Inc., Ann Arbor, Mich. Cure Forward Corp., Cambridge, Mass. Business: Cancer The companies partnered to provide oncology patients with personalized molecular information related to their disease. Results from …

    Published on 8/3/2015
  • Pfizer, Centers for Disease Control and Prevention deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. U.S. Centers for Disease Control and Prevention, Atlanta, Ga. Business: Hematology Pfizer and the CDC partnered to develop a national longitudinal data collection system for sickle…

    Published on 8/3/2015
  • Pierre Fabre Group, Affimed deal

    Pierre Fabre Group, Castres, France Affimed N.V. (NASDAQ:AFMD), Heidelberg, Germany Business: Antibodies Affimeds AbCheck s.r.o. subsidiary and Pierre Fabre expanded their 2014 deal granting Pierre Fabre rights to …

    Published on 8/3/2015
  • RaQualia, Durata Therapeutics deal

    RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Durata Therapeutics Inc., Chicago, Ill. Business: Infectious RaQualia elected to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In …

    Published on 8/3/2015
  • Regeneron, Sanofi deal

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer The companies partnered to jointly develop and commercialize immuno-oncology candidates, …

    Published on 8/3/2015
  • Sanofi, Zai Laboratory deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Zai Laboratory Ltd., Shanghai, China Business: Cancer Sanofi granted Zai exclusive, worldwide rights to develop and commercialize an undisclosed preclinical small molecule …

    Published on 8/3/2015
  • SteadyMed, Cardiome deal

    SteadyMed Ltd. (NASDAQ:STDY), Rehovot, Israel Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Business: Cardiovascular SteadyMed granted Cardiome an exclusive license to commercialize Trevyent in Europe, …

    Published on 8/3/2015
  • Sumitomo Dainippon, JCR Pharmaceuticals deal

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan JCR Pharmaceuticals Co. Ltd. (Tokyo:4552), Ashiya, Japan Business: Neurology, Drug delivery The companies will jointly conduct research using JCRs J-Brain …

    Published on 8/3/2015
  • Tesaro, Jiangsu Hengrui deal

    Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Lianyungang, China Business: Gastrointestinal Tesaro granted Jiangsu Hengrui exclusive rights to develop and commercialize …

    Published on 8/3/2015
  • The Michael Stern Parkinsons Research Foundation, The Michael J. Fox Foundation For Parkinsons Research deal

    The Michael Stern Parkinsons Research Foundation, New York, N.Y. The Michael J. Fox Foundation For Parkinsons Research, New York, N.Y. Business: Neurology The foundations will merge to form the Michael Stern Discovery …

    Published on 8/3/2015
  • Vitae, Boehringer Ingelheim deal

    Vitae Pharmaceuticals Inc. (NASDAQ:VTAE), Fort Washington, Pa. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Neurology Vitae said Boehringer Ingelheim will terminate for strategic business reasons a 2009 …

    Published on 8/3/2015
  • VivaBioCell, NantWorks deal

    VivaBioCell S.p.A., Udine, Italy NantWorks LLC, Los Angeles, Calif. Business: Diagnostic, Gene/Cell therapy NantWorks acquired VivaBioCell for an undisclosed amount. NantWorks gains the companys GMP-in-a-box system used…

    Published on 8/3/2015
  • Zhejiang Wansheng Pharmaceutical, 3SBio deal

    Zhejiang Wansheng Pharmaceutical Co. Ltd., Hangzhou, China 3SBio Inc. (HKSE:1530), Shenyang, China Business: Dermatology, Cancer, Endocrine/Metabolic 3SBio will acquire Zhejiang Wansheng for RMB528 million ($85.1 …

    Published on 8/3/2015
  • AltheRx, Velicept deal

    AltheRx Pharmaceuticals, Exton, Pa. Velicept Therapeutics Inc., Malvern, Pa. Business: Autoimmune, Genitourinary Velicept will merge with AltheRx, and the surviving company will retain Velicepts name and focus on the …

    Published on 7/27/2015
  • ArmaGen, Shire deal

    ArmaGen Technologies Inc., Calabasas, Calif. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment …

    Published on 7/27/2015
  • Bio-Reference Laboratories, Opko deal

    Bio-Reference Laboratories Inc. (NASDAQ:BRLI), Elmwood Park, N.J. Opko Health Inc. (NYSE:OPK;Tel Aviv:OPK), Miami, Fla. Business: Supply/Service Opko will acquire clinical service laboratory Bio-Reference for $1.5 …

    Published on 7/27/2015
  • Bristol-Myers, Genmab deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Cancer Bristol-Myers granted Genmab an exclusive license to a panel of human antibodies targeting CD19 …

    Published on 7/27/2015
  • CleveXel Pharma, PEP-Therapy deal

    CleveXel Pharma S.A.S., Maisons-Alfort, France PEP-Therapy S.A.S., Evry, France Business: Cancer The companies partnered to co-develop a peptide from PEP-Therapy to treat cancer through clinical proof of concept. The …

    Published on 7/27/2015
  • Dara BioSciences, Midatech Pharma deal

    Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Midatech Pharma plc (LSE:MTPH), Abingdon, U.K. Business: Neurology, Infectious Midatech will acquire Dara BioSciences for 5.4 million Midatech shares valued at L15.7 …

    Published on 7/27/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993